Pere Barba
Overview
Explore the profile of Pere Barba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
1924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Camacho-Arteaga L, Iacoboni G, Kwon M, Bailen R, Hernani R, Benzaquen A, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461683.
PMID: 39998830
Importance: Acute adverse events (AEs) after chimeric antigen receptor (CAR) T-cell infusion are well documented, but less information is available regarding the long-term toxic effects. Objective: To assess the occurrence...
2.
Bastos-Oreiro M, Iacoboni G, Garces V, Caballero A, Martinez N, Delgado J, et al.
Hemasphere
. 2025 Feb;
9(2):e70077.
PMID: 39906687
No abstract available.
3.
Roddie C, Sandhu K, Tholouli E, Logan A, Shaughnessy P, Barba P, et al.
N Engl J Med
. 2024 Nov;
391(23):2219-2230.
PMID: 39602653
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. Methods: We conducted...
4.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
5.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, et al.
J Hematol Oncol
. 2024 Oct;
17(1):102.
PMID: 39468591
Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After...
6.
Mingot-Castellano M, Reguera-Ortega J, Zafra Torres D, Hernani R, Lopez-Godino O, Guerreiro M, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274330
Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of...
7.
Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, et al.
Haematologica
. 2024 Aug;
110(1):206-211.
PMID: 39113657
No abstract available.
8.
Sesques P, Kirkwood A, Kwon M, Rejeski K, Jain M, Di Blasi R, et al.
J Hematol Oncol
. 2024 Aug;
17(1):61.
PMID: 39107847
Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and...
9.
Bailen R, Iacoboni G, Delgado J, Lopez-Corral L, Hernani-Morales R, Ortiz-Maldonado V, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):988.e1-988.e11.
PMID: 39069076
Chimeric antigen receptor (CAR)-T cell therapy is approved for the treatment of relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, elderly patients might not be candidates for this therapy due...
10.
Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrian N, Barba P, et al.
Leukemia
. 2024 Jul;
38(9):1985-1991.
PMID: 39043963
COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time...